Clovis Oncology Inc (NASDAQ:CLVS)

Delayed Data
As of Jun 29
 -2.21 / -2.57%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: CO-1686, an oral epidermal growth factor receptor (EGFR), covalent inhibitor currently in Phase I/II development for the treatment of non-small cell lung cancer (NSCLC), in patients with initial activating EGFR mutations as well as the T790M primary resistance mutation; rucaparib, an oral, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase II development for ovarian cancer, which includes the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial) study; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
2525 28th Street
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023



Mutual fund holders46.26%
Other institutional41.82%
Individual stakeholders18.95%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Erle T. MastChief Financial Officer, Secretary & Executive VP
Andrew R. AllenChief Medical Officer & EVP-Clinical Development
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP
Steven L. HoerterChief Commercial Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account